Eventide Investments is a values-driven asset management firm that offers investment strategies that are rooted in the belief that the purpose of business is to serve others. The company integrates financial and values analysis to create portfolios that aim to provide competitive returns while also making a positive impact on the world.

Finny Kuruvilla

Robin Cheriakalath John

Eventide Investments

estos develops software products that enhance communication and collaboration within companies, facilitating the digitization of existing information and communication processes.

estos

Eventide Asset Management, LLC is a Boston-based investment adviser practicing "investing that makes the world rejoice®." Founded in 2008, Eventide's vision is to serve individuals, financial advisors, and institutions by providing high-performance investments that we believe create compelling value for the global common good.

Eventide was named one of Pensions & Investments’ Best Places to Work in Money Management 2022.

For more information on the award methodology please visit: https://www.pionline.com/best-places-to-work/2022

For our Social Media Terms of Use and additional disclosures, please visit:
https://www.eventideinvestments.com/social-media-guidelines/

Zentalis Pharmaceuticals

Talaris Therapeutics

Karuna Therapeutics

Annexon Biosciences

Magenta Therapeutics

Collegium Pharmaceutical

Cullinan Oncology

Dice Therapeutics

Roivant Sciences

Pliant Therapeutics

Praxis Precision Medicines

Freeline

Prometheus Biosciences

Eventide Asset Management

We are hiring! 

Eventide Asset Management is hiring a Head of Marketing & Communications and a Director of Digital Marketing. These roles will be a driving force in our journey towards principled, faith-driven investing!  As a key member of the CEO's executive team, the Head of Marketing and Communications will spearhead the development of a marketing-centric organizational culture and will be essential in leading us toward excellence. The Director of Digital Marketing will lead a digital transformation agenda that amplifies Eventide's brand experience.

We are looking for leaders with excellence and a passion for Eventide's mission. Eventide employees work hard for the sake of others—our clients, our colleagues, and our world. Our mission is to honor God and serve our clients through investments that make the world rejoice.

Read more about these careers here: https://lnkd.in/dsPS3y79

If you are interested, please send your CV and cover letter to careers@eventideinvestments.com, and a member of our Human Resources department will be in touch with you!

Join us at 3pm ET this afternoon to hear from Dr. Finny Kuruvilla in our quarterly CIO Update.

This webinar will be a 2024 macro look ahead that shares our "three legs of the stool" approach to evaluating the health of the markets–considering leading economic indicators, valuation, and sentiment.

We are excited to see you there! 

Register here: https://lnkd.in/gm2cB4uk

"We are closer than ever to a more amenable environment for biotech,” shared Eventide’s Kyle R. with Investor's Business Daily in today’s feature about 2024 biotech expectations. 

In this article, Kyle R. shares Eventide’s optimism of enhancing the quality of life for individuals and communities through the developments emerging in the biotech industry. 

Read more here: https://lnkd.in/gHxzNdHN

#PharmaIndustry #Biotech2024 #Alzheimers

Join us next week on Thursday, January 18th, at 3pm ET to hear from Dr. Finny Kuruvilla in our quarterly CIO Update.

This webinar shares our "three legs of the stool" approach to evaluating the health of the markets–considering leading economic indicators, valuation, and sentiment. 

We hope to see you there!

Some investment strategies are active, while others are passive. Investors using the more active approaches often strategize to pursue higher returns than the rest of the market—a concept referred to as “alpha.” Check out this recent episode on Faith and Finance Live, where host Rob West and Shaun Morgan from Eventide discuss a fourth source of alpha that Christian investors may want to consider.

Morningstar recently highlighted Eventide as a “fast-growing firm” in its feature on faith-based investing. Our CEO, Robin Cheriakalath John, underscored Eventide’s dual mandate of seeking performance and a better world. Robin explained, “We believe companies that serve stakeholders well will ultimately do better in the long term. That’s good news for all investors regardless of your background.”

Read the piece here: https://lnkd.in/gpU36hHe

#valuesbasedinvesting #Christianfinance

Newsweek recently published an article by Eventide Asset Management’s Kyle Rasbach about emerging new therapies for brain disorders like schizophrenia. After decades of stagnation, the industry is finally seeing innovative treatment options develop that could genuinely transform outcomes for patients and society. 

As investors, we are currently in a unique time where we can come together to advance human flourishing by funding innovation in #biotech while also generating long-term financial returns. 

Read Kyle’s entire piece here: https://lnkd.in/eJYsRGQn

#healthcareinnovation #pharma #pharmaceuticals #mentalhealth #brainhealth #medicine #investing

Eventide is happy to be a local host of the 2024 Faith Driven Investor  Conference Watch Party: Build. Give. Invest. The event will be held on January 24th at our headquarters in Boston. For more information and to register, please visit https://lnkd.in/gNvvhtVW.

To register for a watch party near you, visit https://lnkd.in/gS5pt7xa.

Eventide's Kyle Rasbach spoke with Investor's Business Daily about the breakthroughs in treating Alzheimer's.

Kyle discusses how the future of Alzheimer's treatments relies on creating powerful drugs that can decrease beta-amyloid—an amino acid present in the brains of Alzheimer's patients—without causing as much brain swelling.

Scientists have already made promising strides in preventing the deterioration of the human brain, and their ongoing efforts will uncover solutions for treating Alzheimer's.

#PharmaIndustry #Biotech #Alzheimers

“I think sometimes people start with profit as a kind of motive–and it’s very easy to get discouraged when it’s all self-centered in that way.”– Eventide Asset Management CEO Robin Cheriakalath John 

Listen to the discussion between Stacy Havener and Robin Cheriakalath John on Billion Dollar Backstory Podcast, as they explore the challenges of launching Eventide with no track record, no assets, but an unwavering belief.

#investing #values #mission

Metric
Company Name	Eventide Investments	estos
Symbol
MSH ID	COM:EVENTIDEINVESTMENTS	DE:ESTOS
Market	PRIVATE	PRIVATE
Sector	Financial Services & Finance	Technology
Industry	Financial Services	Software and IT Services
Country	US	DE
Stage
Employee Count	79
Website	eventideinvestments.com	estos.de
LinkedIn	eventideassetmanagement
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic	33.79K	17.95K
Web Traffic Growth	3.82	0.43
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:EVENTIDEINVESTMENTS

Eventide Investments

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue